AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Is ABBV a Buy, Before Earnings?
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- AbbVie reports ‘positive’ results from Phase 3 SELECT-GCA study of upadacitinib
- Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally
- AbbVie Stock (NYSE:ABBV): Humira Leads Market with 96% Share